Efficacy and Safety of Delayed, Low-Dose Valganciclovir in High-Risk Cytomegalovirus Liver Transplant Recipients.

被引：0
|
作者：
Anders, S. [1 ]
Freeman, A. [1 ]
Hutchinson, L. [1 ]
Kaszubski, U. [1 ]
Janusek, M. [1 ]
Hooter, A. [2 ]
Raymond, D. [2 ]
Nguyen, C. [2 ]
机构：
[1] Ochsner Med Ctr, New Orleans, LA USA
[2] Xavier Univ, New Orleans, LA 70125 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
D161
引用
收藏
页码：1075 / 1075
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of low-dose valganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients.
    Park, JM
    Arenas, JD
    Fontana, RJ
    Lake, KD
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 502 - 502
  • [2] Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
    Park, JM
    Lake, KD
    Arenas, JD
    Fontana, RJ
    [J]. LIVER TRANSPLANTATION, 2006, 12 (01) : 112 - 116
  • [3] Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Bixby, Alexandra L.
    Fitzgerald, Linda
    Park, Jeong M.
    Kaul, Daniel
    Tischer, Sarah
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
  • [4] Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. (vol 12, pg 112, 2006)
    Park, JM
    Lake, KD
    Arenas, JD
    Fontana, RJ
    [J]. LIVER TRANSPLANTATION, 2006, 12 (03) : 494 - 494
  • [5] Low dose valganciclovir in liver transplant recipients.
    Dupuis, R
    Harris, M
    Andreoni, K
    Gerber, D
    Conoley, R
    Fair, J
    VanBeuge, D
    Johnson, M
    Watson, R
    Shrestha, R
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 167 - 167
  • [6] Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients.
    Bixby, A. L.
    Fitzgerald, L.
    Cotiguala, L.
    Park, J. M.
    Kaul, D.
    Sonnenday, C.
    Tischer, S.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 720 - 721
  • [7] Efficacy of Two Valganciclovir Dosing Strategies in Intermediate and High-Risk Liver Transplant Recipients.
    Belfield, K.
    Malinis, M.
    Cohen, E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 878 - 878
  • [8] Efficacy and safety of valganciclovir in prophylaxis of cytomegalovirus disease in renal transplant recipients.
    Gabardi, S
    Powelson, J
    Baroletti, SA
    Cina, JL
    Goggins, WC
    [J]. PHARMACOTHERAPY, 2003, 23 (03): : 412 - 413
  • [9] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237
  • [10] EFFICACY AND SAFETY OF LOW DOSE VERSUS HIGH DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN INTERMEDIATE RISK KIDNEY TRANSPLANT RECIPIENTS
    Halim, Medhat Abdel
    Al-Otaibi, Torki
    Gheith, Osama
    Adel, Hany
    Mosaad, Ahmed
    Abu-Atteya, Hassaneen
    Zakaria, Zakaria
    Makkeya, Yahia
    Said, Tarek
    Nair, Prasad
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 1568 - 1569
12345